Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMIX Autonomix Medical	$1.34 +8.1%	$1.73	$1.14 ▼ $42.40	$3.45M	-3.47	336,625 shs	143,223 shs
CHEK Check-Cap	$0.75 +1.6%	$0.80	$0.56 ▼ $3.04	$4.32M	0.22	377,677 shs	107,657 shs
NUWE Nuwellis	$0.30 +10.7%	$0.77	$0.21 ▼ $8.23	$1.17M	0.48	3.39 million shs	7.42 million shs
NVIVQ InVivo Therapeutics	$0.37	$0.37	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMIX Autonomix Medical	+8.06%	+7.20%	-23.86%	-33.33%	-93.62%
CHEK Check-Cap	+1.56%	0.00%	-11.51%	-15.73%	-64.87%
NUWE Nuwellis	+10.70%	+5.68%	-68.13%	-73.35%	-95.98%
NVIVQ InVivo Therapeutics	0.00%	0.00%	0.00%	0.00%	+36,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMIX Autonomix Medical	2.4009 of 5 stars	3.5	2.0	0.0	0.0	1.1	1.7	1.3
CHEK Check-Cap	0.4557 of 5 stars	0.0	5.0	0.0	0.0	0.0	0.0	0.6
NUWE Nuwellis	2.6249 of 5 stars	3.5	5.0	0.0	0.0	0.6	0.0	1.3
NVIVQ InVivo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMIX Autonomix Medical	3.00	Buy	$16.50	1,131.34% Upside
CHEK Check-Cap	0.00	N/A	N/A	N/A
NUWE Nuwellis	3.00	Buy	$17.00	5,647.13% Upside
NVIVQ InVivo Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVIVQ, NUWE, AMIX, and CHEK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/13/2025	NUWE Nuwellis	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/29/2025	AMIX Autonomix Medical	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMIX Autonomix Medical	N/A	N/A	N/A	N/A	$3.29 per share	N/A
CHEK Check-Cap	N/A	N/A	N/A	N/A	$4.05 per share	N/A
NUWE Nuwellis	$8.74M	0.15	N/A	N/A	$1.49 per share	0.20
NVIVQ InVivo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMIX Autonomix Medical	-$11.41M	-$7.47	N/A	N/A	N/A	N/A	-174.70%	-133.35%	N/A
CHEK Check-Cap	-$17.57M	-$3.00	N/A	∞	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	-$11.16M	-$18.24	N/A	N/A	N/A	-112.09%	-655.31%	-141.83%	8/12/2025 (Estimated)
NVIVQ InVivo Therapeutics	-$10.49M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest NVIVQ, NUWE, AMIX, and CHEK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/29/2025	Q4 2025	AMIX Autonomix Medical	N/A	-$0.74	N/A	-$0.74	N/A	N/A
5/13/2025	Q1 2025	NUWE Nuwellis	-$0.45	-$0.69	-$0.24	-$0.69	$2.50 million	$1.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMIX Autonomix Medical	N/A	N/A	N/A	N/A	N/A
CHEK Check-Cap	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	N/A	N/A	N/A	N/A	N/A
NVIVQ InVivo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMIX Autonomix Medical	N/A	5.63	5.63
CHEK Check-Cap	N/A	N/A	N/A
NUWE Nuwellis	N/A	2.23	1.59
NVIVQ InVivo Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMIX Autonomix Medical	10.78%
CHEK Check-Cap	1.07%
NUWE Nuwellis	3.13%
NVIVQ InVivo Therapeutics	12.32%

Insider Ownership

Company	Insider Ownership
AMIX Autonomix Medical	32.40%
CHEK Check-Cap	0.48%
NUWE Nuwellis	2.60%
NVIVQ InVivo Therapeutics	2.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMIX Autonomix Medical	1	2.78 million	1.88 million	N/A
CHEK Check-Cap	80	5.85 million	5.82 million	Not Optionable
NUWE Nuwellis	70	4.37 million	4.26 million	Not Optionable
NVIVQ InVivo Therapeutics	6	N/A	N/A	N/A

NVIVQ, NUWE, AMIX, and CHEK Headlines

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVIVQ, NUWE, AMIX, and CHEK Company Descriptions

Autonomix Medical NASDAQ:AMIX

$1.34 +0.10 (+8.06%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$1.30 -0.04 (-2.99%)

As of 06:17 AM Eastern

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

Check-Cap NASDAQ:CHEK

$0.75 +0.01 (+1.56%)

Closing price 06/23/2025 03:58 PM Eastern

Extended Trading

$0.76 +0.01 (+1.33%)

As of 05:17 AM Eastern

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

Nuwellis NASDAQ:NUWE

$0.30 +0.03 (+10.70%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$0.27 -0.02 (-7.71%)

As of 06:53 AM Eastern

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

InVivo Therapeutics NASDAQ:NVIVQ

$0.37 0.00 (0.00%)

As of 07/26/2024

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time